FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097165105> ?p ?o ?g. }

• W2097165105 endingPage "1675" @default.
• W2097165105 startingPage "1667" @default.
• W2097165105 abstract "To evaluate the efficacy and safety of subcutaneous blisibimod, an inhibitor of B cell activating factor, in patients with systemic lupus erythematosus (SLE) in a dose-ranging Phase 2b clinical trial.547 patients with SLE with anti-double stranded DNA or antinuclear antibodies and Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI) score ≥6 at baseline were randomised to receive placebo or blisibimod at one of 3 dose levels. The primary end point, measured at Week 24, was the SLE Responder Index-5 (SRI-5, meeting established SRI criteria but with ≥5 point improvement in SELENA-SLEDAI).Although SRI-5 response rates were not significantly improved in the pooled blisibimod groups compared with placebo, they were higher in subjects randomised to the highest dose of blisibimod (200 mg once-weekly (QW)) compared with pooled placebo, from Week 16 to Week 24, reaching statistical significance at Week 20 (p=0.02). SRI response rates compared with placebo were higher still in subjects who attained SELENA-SLEDAI improvements of ≥8, and in a subgroup of patients with severe disease (SELENA-SLEDAI ≥10 and receiving corticosteroids at baseline). In subjects with protein:creatine ratios of 1-6 at baseline, significant reductions in proteinuria were observed with blisibimod. Significant (p<0.01) changes in anti-double stranded DNA antibodies, complement C3 and C4, and reductions in B cells were observed with blisibimod.No imbalances in serious adverse events or infections (4/280 and 3/266), deaths (4/280 and 3/266) and malignancies (2/280 and 2/266) were reported for blisibimod compared with placebo.This study successfully identified a safe, effective and convenient dose, study population and end point for evaluation of blisibimod effect in Phase 3.NCT01162681." @default.
• W2097165105 created "2016-06-24" @default.
• W2097165105 creator A5006919099 @default.
• W2097165105 creator A5024571354 @default.
• W2097165105 creator A5075702830 @default.
• W2097165105 creator A5076651506 @default.
• W2097165105 creator A5078727612 @default.
• W2097165105 creator A5082713013 @default.
• W2097165105 creator A5086018261 @default.
• W2097165105 creator A5090392559 @default.
• W2097165105 date "2014-04-19" @default.
• W2097165105 modified "2023-10-17" @default.
• W2097165105 title "A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study" @default.
• W2097165105 cites W1625166229 @default.
• W2097165105 cites W1975085076 @default.
• W2097165105 cites W1996845474 @default.
• W2097165105 cites W2033483715 @default.
• W2097165105 cites W2064999867 @default.
• W2097165105 cites W2076992868 @default.
• W2097165105 cites W2087785715 @default.
• W2097165105 cites W2091468965 @default.
• W2097165105 cites W2106574491 @default.
• W2097165105 cites W2113864921 @default.
• W2097165105 cites W2114638396 @default.
• W2097165105 cites W2119296184 @default.
• W2097165105 cites W2126846485 @default.
• W2097165105 cites W2131154673 @default.
• W2097165105 cites W2131457901 @default.
• W2097165105 cites W2136149088 @default.
• W2097165105 cites W2141455950 @default.
• W2097165105 cites W2152853007 @default.
• W2097165105 cites W2157487266 @default.
• W2097165105 cites W2170524712 @default.
• W2097165105 cites W4241966887 @default.
• W2097165105 doi "https://doi.org/10.1136/annrheumdis-2013-205144" @default.
• W2097165105 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24748629" @default.
• W2097165105 hasPublicationYear "2014" @default.
• W2097165105 type Work @default.
• W2097165105 sameAs 2097165105 @default.
• W2097165105 citedByCount "124" @default.
• W2097165105 countsByYear W20971651052014 @default.
• W2097165105 countsByYear W20971651052015 @default.
• W2097165105 countsByYear W20971651052016 @default.
• W2097165105 countsByYear W20971651052017 @default.
• W2097165105 countsByYear W20971651052018 @default.
• W2097165105 countsByYear W20971651052019 @default.
• W2097165105 countsByYear W20971651052020 @default.
• W2097165105 countsByYear W20971651052021 @default.
• W2097165105 countsByYear W20971651052022 @default.
• W2097165105 countsByYear W20971651052023 @default.
• W2097165105 crossrefType "journal-article" @default.
• W2097165105 hasAuthorship W2097165105A5006919099 @default.
• W2097165105 hasAuthorship W2097165105A5024571354 @default.
• W2097165105 hasAuthorship W2097165105A5075702830 @default.
• W2097165105 hasAuthorship W2097165105A5076651506 @default.
• W2097165105 hasAuthorship W2097165105A5078727612 @default.
• W2097165105 hasAuthorship W2097165105A5082713013 @default.
• W2097165105 hasAuthorship W2097165105A5086018261 @default.
• W2097165105 hasAuthorship W2097165105A5090392559 @default.
• W2097165105 hasConcept C126322002 @default.
• W2097165105 hasConcept C142724271 @default.
• W2097165105 hasConcept C149443304 @default.
• W2097165105 hasConcept C159654299 @default.
• W2097165105 hasConcept C163764329 @default.
• W2097165105 hasConcept C180296930 @default.
• W2097165105 hasConcept C197934379 @default.
• W2097165105 hasConcept C203014093 @default.
• W2097165105 hasConcept C203092338 @default.
• W2097165105 hasConcept C204787440 @default.
• W2097165105 hasConcept C27081682 @default.
• W2097165105 hasConcept C2775915377 @default.
• W2097165105 hasConcept C2776912625 @default.
• W2097165105 hasConcept C2779134260 @default.
• W2097165105 hasConcept C2779561371 @default.
• W2097165105 hasConcept C2779912601 @default.
• W2097165105 hasConcept C2780091579 @default.
• W2097165105 hasConcept C535046627 @default.
• W2097165105 hasConcept C71924100 @default.
• W2097165105 hasConcept C90924648 @default.
• W2097165105 hasConceptScore W2097165105C126322002 @default.
• W2097165105 hasConceptScore W2097165105C142724271 @default.
• W2097165105 hasConceptScore W2097165105C149443304 @default.
• W2097165105 hasConceptScore W2097165105C159654299 @default.
• W2097165105 hasConceptScore W2097165105C163764329 @default.
• W2097165105 hasConceptScore W2097165105C180296930 @default.
• W2097165105 hasConceptScore W2097165105C197934379 @default.
• W2097165105 hasConceptScore W2097165105C203014093 @default.
• W2097165105 hasConceptScore W2097165105C203092338 @default.
• W2097165105 hasConceptScore W2097165105C204787440 @default.
• W2097165105 hasConceptScore W2097165105C27081682 @default.
• W2097165105 hasConceptScore W2097165105C2775915377 @default.
• W2097165105 hasConceptScore W2097165105C2776912625 @default.
• W2097165105 hasConceptScore W2097165105C2779134260 @default.
• W2097165105 hasConceptScore W2097165105C2779561371 @default.
• W2097165105 hasConceptScore W2097165105C2779912601 @default.
• W2097165105 hasConceptScore W2097165105C2780091579 @default.
• W2097165105 hasConceptScore W2097165105C535046627 @default.
• W2097165105 hasConceptScore W2097165105C71924100 @default.

• next